Dendreon is pushing ahead with a new late-stage study of Provenge, completing enrollment in a new Phase III trial the FDA has demanded before it can grant full approval for the cancer therapy. Release
Dendreon is pushing ahead with a new late-stage study of Provenge, completing enrollment in a new Phase III trial the FD
